Wockhardt News, Corporate filings and Earnings/Conference Calls

Keep track of all breaking news and updates on Wockhardt from all sources in a single place.

29 May 2026, 01:23PM

2031.40

14.70%

Wockhardt hits all-time high on CDSCO approval for antibiotic Zaynich

Business Standard

The buying on the counter came after the company received approval from the CDSCO for the import and marketing of Zaynich Zidebactam/Cefepime

Wockhardt has gained 64.49% in the last 6 Months

Wockhardt Ltd.

28 May 2026, 04:41PM

2031.40

14.70%

Company Update

Wockhardt Ltd - 532300 - Compliances-Reg.24(A)-Annual Secretarial Compliance

BSE India

Pursuant to Regulation 24A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith the Annual Secretarial Compliance Report for the year ended 31st March, 2026

pdf

Wockhardt Ltd.

28 May 2026

2031.40

14.70%

Company Update

Wockhardt Ltd - 532300 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Pursuant to Regulation 30 of Listing Regulations, please find enclosed Press Release - "Indian drug regulator grants marketing authorization to Wockhardt''s breakthrough antibiotic , ZAYNICH (Zidebactum/ Cefepime), for treatment of complicated urinary tract infections including pyelonephritis with concurrent Gram- negative bacteremia"

pdf

Wockhardt Ltd.

21 May 2026

2031.40

14.70%

Company Update

Wockhardt Ltd - 532300 - Announcement under Regulation 30 (LODR)-Credit Rating

BSE India

ICRA Limited has upgraded the Credit Rating as given below: Long Term- Fund Based- Term Loan- Present Rating- A- (Stable); Previous Rating- BBB (Positive) Long Term/ Short Term- Fund Based- Present Rating- A- (Stable)/ A2+; Previous Rating- BBB (Positive)/ A3+ Long Term/ Short Term- Non Fund Based- Present rating- A(Stable)/ A2+; Previous Rating- BBB(Positive)/ A3+ Long Term/Short Term- Unallocated Limits- Present Rating -A (Stable)/ A2+; Previous rating- BBB (Positive)/ A3+

pdf